AlphAIAlphAI — Financial news for AI agents
ibtimes.com.auSEP 292 min read

Iovance Biotherapeutics Stock Soars 20% After Cancer Therapy Maker Raises 2026 Revenue Forecast Sharply

Iovance Biotherapeutics' shares surged 20% after raising its 2026 revenue forecast to $410M-$420M, up from $350M-$370M, citing strong demand for its melanoma treatment Amtagvi. The company reported Q2 revenue of $99.3M with a 56% gross margin. Analysts have turned bullish, with Goldman Sachs and Barclays setting price targets at $15. The stock has gained over 300% YTD, reaching a $5B market cap.

Original reporting
ibtimes.com.au
Published Sep 29, 2026, 1:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 3:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Iovance Biotherapeutics Stock Soars 20% After Cancer Therapy Maker Raises 2026 Revenue Forecast Sharply — source image
Source · ibtimes.com.au
Decision brief

The 30-second read

High
01

Why it matters

The guidance raise validates commercial rollout and may attract new institutional buying.

02

Market read

Iovance's guidance lift and 20% price surge present a clear short‑term buying opportunity in the biotech space.

03

What to watch

Potential dilution from upcoming stock option grants and cash‑burn concerns could temper upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Iovance recently expanded its treatment‑center network to ~100 sites and received FDA approval for Amtagvi in 2024.

Market effects

Sector

Boosts sentiment for cell‑therapy biotech sector and may lift peers with similar pipelines.

Regional

Positive for US biotech stocks, especially those listed on NASDAQ.

Global

Limited to biotech investors; no broad macro impact.

Counterpoint

What could challenge this read

Risk remains high due to unprofitable status and manufacturing complexity; a pull‑back could occur if lung‑cancer data disappoints.

Key entities

  • Executive
    Frederick Vogt

    Interim President and CEO who highlighted the strong Q2 results.

  • Analyst
    Goldman Sachs

    Resumed coverage with a $15 price target, supporting the rally.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 29
$IOVAHighAI 8/10

Iovance shares jump in premarket as raised outlook clears consensus views

Iovance Biotherapeutics (IOVA) shares rose 14% premarket after raising its 2026 revenue outlook to $410M-$420M, exceeding consensus estimates. The company cited strong adoption of Amtagvi and Proleukin, expanding its treatment network to 100 locations. IOVA aims for profitability through operational efficiencies and manufacturing improvements. Q3 results are due in early November.

investing.com1 min
SEP 29
$IOVAHighAI 9/10

Why is Iovance Biotherapeutics stock surging today?

Iovance Biotherapeutics (IOVA) stock rose 10.5% in pre-market trading after raising its 2026 revenue guidance to $410–$420M, up from $350–$370M, citing strong demand for Amtagvi and Proleukin. The company reported Q2 revenue of $99.3M with a 56% gross margin. Goldman Sachs resumed coverage with a Buy rating and $15 target.

investing.com2 min